Johnson & Johnson — FY2012 Form 10-K
Reporting period: Fiscal year ended December 30, 2012; filed February 21, 2013. This is an annual report, not a standalone fourth-quarter report. Johnson & Johnson is a global health-care company operating through Consumer, Pharmaceutical, and Medical Devices and Diagnostics segments.
Financial and operating highlights
- Revenue, profit, cash flow, margins, debt, and liquidity: The filing incorporates the audited financial statements and management discussion from the 2012 Annual Report, but those figures are not included in the supplied text. The filing text provided here does not give clear values for these metrics.
- Research and development: Worldwide R&D expense was $7.7 billion in 2012, compared with $7.5 billion in 2011 and $6.8 billion in 2010.
- Product concentration: REMICADE, the company’s largest product, represented approximately 9.1% of 2012 total revenue.
- Reserves: The schedule of valuation and qualifying accounts reports total balances of $4.182 billion at year-end 2012 and $3.753 billion at year-end 2011. These include rebate, returns, promotions, doubtful-account, and cash-discount reserves.
- Scale: Approximately 127,600 employees; more than 275 operating companies in 60 countries.
Changes versus prior periods
- R&D expense increased about 3% from 2011 and 13% from 2010.
- U.S. LEVAQUIN sales declined approximately 94% in 2012 versus 2011 after losing U.S. market exclusivity in June 2011 and facing generic competition.
- McNeil Consumer Healthcare production remained constrained by additional reviews under an FDA consent decree. The company expected these effects to continue through most of 2013.
- The company stated that it made no open-market share purchases in fiscal Q4 2012; the 324,114 reported shares purchased resulted from stock-for-stock option exercises. No shares were purchased under publicly announced plans in the quarter.
Outlook, risks, and unusual items
- Outlook: No consolidated financial guidance is stated in the supplied filing text. Management expected the McNeil facility constraints and related production effects to persist through most of 2013; plants under the consent decree were to focus on a simplified portfolio of key brands.
- Regulatory and market risks: The company cited increasingly stringent product regulation, higher testing and documentation costs, scrutiny of health-care pricing and business practices, and uncertainty about the effects of the Affordable Care Act.
- Legal and compliance matters: The filing refers to legal proceedings detailed in the incorporated Annual Report. Separately, California regulators alleged waste-handling violations at a subsidiary facility; the company said it believed it had adequate defenses and expected resolution without significant penalties or other adverse impact. The ultimate outcome was not predictable.
- Other exposures: International operations may face political and economic uncertainty. Competition, patent protection, product recalls or withdrawals, and the availability of key products and manufacturing capacity are also relevant risks.
- Controls: The CEO and CFO concluded that disclosure controls were effective at year-end; no material change in internal control over financial reporting was identified during the fourth quarter.
Investor facts to verify
- Review the incorporated Annual Report for complete 2012 and comparative revenue, earnings, cash-flow, margin, debt, liquidity, segment, and guidance figures; they are not clearly provided in the supplied text.
- Assess REMICADE concentration and the impact of generic competition on products losing exclusivity.
- Track FDA consent-decree remediation, McNeil production recovery, and any continuing supply or quality effects.
- Review the full legal-proceedings and risk-factor disclosures, including the incorporated details not reproduced in the supplied text.
- Confirm the company’s 2013 outlook and the effects of health-care regulation and pricing pressures against the complete filing and subsequent disclosures.